Vyteris and Zealand Pharma collaborate to increase delivery options for peptides
Vyteris, a US developer of the first FDA-approved active transdermal drug delivery system, is to work with Zealand Pharma, a Denmark-based developer of peptide-based drugs. The aim is to apply Vyteris' technology to the controlled transdermal delivery of Zealand Pharma's peptide optimisation technology.
Vyteris, a US developer of the first FDA-approved active transdermal drug delivery system, is to work with Zealand Pharma, a Denmark-based developer of peptide-based drugs. The aim is to apply Vyteris' technology to the controlled transdermal delivery of Zealand Pharma's peptide optimisation technology.
"This strategic partnership marks another milestone in the active roll-out of our patented smart patch transdermal technology for the delivery of high-value, therapeutic peptides," said Dr Haro Hartounian, president and chief executive of Vyteris.
"Tightly controlled delivery of peptides via active, transdermal patches is an innovative and patient-friendly route of administration which can lead to increased safety and compliance. Our ongoing female infertility project with Ferring Pharmaceuticals has now entered clinical phase II, and we hope to continue this success in transdermal peptide delivery with our new partner Zealand Pharma," he added.
In the first phase of this collaboration, the companies will test the feasibility of smart patch-based transdermal delivery of a peptide drug candidate in animal models. Upon completion of this study, the companies could decide to further develop and commercialise the peptide or others in Zealand Pharma's product portfolio.
"We believe this represents a strong collaborative effort to develop innovative new methods of peptide drug delivery that may have significant advantages in efficacy, patient compliance and tolerability," said David Solomon, chief executive officer of Zealand Pharma.
